In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ’s Make Or Break Moment Comes Down To Business Development

Executive Summary

AstraZeneca needs new assets to change investors’ dismal outlook for the company. With a new CEO installed, an R&D shakeup underway, and a new portfolio strategist joining in May, AstraZeneca will embark on an ambitious acquisition and partnering strategy in 2013.

Advertisement

Related Content

Dunoyer Makes Leap To CFO As AZ’s BD Overhaul Continues
AZ’s Upbeat Pipeline Message Tarnished By Federal Probes, Poor Sales
Venture Creation Story: The Early Days Of Moderna
AZ Centers Pearl As The Jewel Of Its Respiratory Franchise
Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
Biopharma Dealmaking Quarterly Statistics, Q1 2013
Is Brilinta The Treatment To Keep AstraZeneca’s Lifeblood Flowing?
AstraZeneca’s Executive Shakeup Includes Global Strategist To Be Named Later
GSK Is Getting Ready For A Return To The ’90s

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel